{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-055484","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2026-08-11T10:59:00+00:00","discovered_at":"2026-08-11T11:00:00.728638+00:00","generated_at":"2026-08-11T11:00:13.712921+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Shattuck Labs Q2 net loss widens to $15.2M; cash $208M; SL-325 Phase 1 positive","bullets":["Q2 2026 net loss $15.2M ($0.12/sh) vs $12.5M ($0.24/sh) in Q2 2025; R&D $11.7M, G&A $4.5M.","Cash, equivalents and short-term investments $208.3M at 6/30/26, expected to fund operations into 2029.","SL-325 Phase 1: 3.7% ADA, >3-month DR3 blockade at ≥1mg/kg, favorable safety, no DR3 agonism.","RECEPTIVE-CD1 Phase 2b Crohn's starts Q3 2026: ~232 pts, primary endpoint endoscopic response at 12 wks, data 1H 2028.","SL-846 bispecific (DR3 x IL-23R) in IND-enabling tox; Phase 1 healthy volunteer trial expected 2027; poster at UEGW Oct 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-055484","json":"https://secwatch.observer/filing/0001628280-26-055484.json","markdown":"https://secwatch.observer/filing/0001628280-26-055484.md","text":"https://secwatch.observer/filing/0001628280-26-055484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000162828026055484/0001628280-26-055484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000162828026055484/sttk-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:00:13.712921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}